Munich - Delayed Quote EUR
Insulet Corp (GOV.MU)
229.10
+2.00
+(0.88%)
At close: April 25 at 5:26:05 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
2,071,600
2,071,600
1,697,100
1,305,300
1,098,800
Cost of Revenue
625,900
625,900
537,200
499,700
346,700
Gross Profit
1,445,700
1,445,700
1,159,900
805,600
752,100
Operating Expense
1,136,800
1,136,800
939,900
768,000
626,100
Operating Income
308,900
308,900
220,000
37,600
126,000
Net Non Operating Interest Income Expense
-3,200
-3,200
-7,600
-26,700
-61,200
Other Income Expense
-5,500
-5,500
2,200
-1,100
-44,300
Pretax Income
300,200
300,200
214,600
9,800
20,500
Tax Provision
-118,100
-118,100
8,300
5,200
3,700
Net Income Common Stockholders
418,300
418,300
206,300
4,600
16,800
Diluted NI Available to Com Stockholders
418,300
418,300
206,300
4,600
16,800
Basic EPS
5.97
--
2.96
0.07
0.25
Diluted EPS
5.78
--
2.94
0.07
0.24
Basic Average Shares
70,076
--
69,751
69,375
67,698
Diluted Average Shares
73,890
--
73,633
69,910
68,579
Total Operating Income as Reported
308,900
308,900
220,000
37,600
126,000
Total Expenses
1,762,700
1,762,700
1,477,100
1,267,700
972,800
Net Income from Continuing & Discontinued Operation
418,300
418,300
206,300
4,600
16,800
Normalized Income
418,300
418,300
206,300
4,600
51,483.20
Interest Income
39,500
39,500
28,600
9,300
500
Interest Expense
42,700
42,700
36,200
36,000
61,700
Net Interest Income
-3,200
-3,200
-7,600
-26,700
-61,200
EBIT
342,900
342,900
250,800
45,800
82,200
EBITDA
423,700
423,700
323,600
109,000
139,600
Reconciled Cost of Revenue
625,900
625,900
537,200
499,700
346,700
Reconciled Depreciation
80,800
80,800
72,800
63,200
57,400
Net Income from Continuing Operation Net Minority Interest
418,300
418,300
206,300
4,600
16,800
Total Unusual Items Excluding Goodwill
--
--
--
--
-42,400
Total Unusual Items
--
--
--
--
-42,400
Normalized EBITDA
423,700
423,700
323,600
109,000
182,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
--
--
--
--
-7,716.80
12/31/2021 - 7/9/2010
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CBLL CeriBell, Inc.
15.31
-1.16%
IART Integra LifeSciences Holdings Corporation
16.81
+0.66%
ATEC Alphatec Holdings, Inc.
11.51
+0.96%
RBOT Vicarious Surgical Inc.
8.47
+27.37%
INSP Inspire Medical Systems, Inc.
159.06
+0.54%
GMED Globus Medical, Inc.
72.80
-0.37%
BSX Boston Scientific Corporation
101.90
+0.75%